PPARA and prostate cancer: PPAR modulators have demonstrated antitumor activity in xenograft models of breast and prostate cancer [10], sometimes displaying synergy with retinoids, probably due, in part, to the fact that PPAR binds DNA as a heterodimer with RXR.